Oragenics is focused on developing effective treatments for oral mucositis and becoming a leader in developing novel antibiotics against infectious diseases. Oragenics, Inc. has established two exclusive worldwide channel collaborations with Precigen, Inc., a synthetic biology company. The collaborations allow Oragenics access to Precigen's proprietary technologies toward the goal of accelerating the development of much needed new antibiotics that can work against resistant strains of bacteria and the development of biotherapeutics for oral mucositis and other diseases and conditions of the oral cavity, throat, and esophagus.
Oragenics, Inc. was founded in 1996 by Dr. Jeffrey Hillman and Dr. Robert Zahradnik on the concept of Replacement Therapy.
Building Shareholder Value Through Strong Leadership
We are well equipped with a team that is capable of taking our products to the next level.